Etrasimod for the treatment of ulcerative colitis.
Type de document :
Article dans une revue scientifique: Article de synthèse/Review paper
DOI :
PMID :
URL permanente :
Titre :
Etrasimod for the treatment of ulcerative colitis.
Auteur(s) :
Wils, Pauline [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Peyrin-Biroulet, Laurent [Auteur]
Centre Hospitalier Régional Universitaire de Nancy [CHRU Nancy]
Centre Hospitalier Universitaire de Nancy [CHU Nancy]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Peyrin-Biroulet, Laurent [Auteur]
Centre Hospitalier Régional Universitaire de Nancy [CHRU Nancy]
Centre Hospitalier Universitaire de Nancy [CHU Nancy]
Titre de la revue :
Immunotherapy
Nom court de la revue :
Immunotherapy
Date de publication :
2023-02-16
ISSN :
1750-7448
Mot(s)-clé(s) en anglais :
etrasimod
inflammatory bowel disease
S1PR modulator
sphingosine-1-phosphate
ulcerative colitis
inflammatory bowel disease
S1PR modulator
sphingosine-1-phosphate
ulcerative colitis
Résumé en anglais : [en]
Sphingosine-1-phosphate (S1P) and its receptor (S1PR) are involved in the pathogenesis of multiple immune-mediated inflammatory disorders, including inflammatory bowel disease. The use of S1PR modulators represents a new ...
Lire la suite >Sphingosine-1-phosphate (S1P) and its receptor (S1PR) are involved in the pathogenesis of multiple immune-mediated inflammatory disorders, including inflammatory bowel disease. The use of S1PR modulators represents a new therapeutic option for ulcerative colitis patients. Etrasimod is an oral selective S1PR1, S1PR4 and S1PR5 modulator that inhibits the trafficking of lymphocytes from the lymph nodes into the blood. Recently, etrasimod has demonstrated efficacy in the phase II OASIS study and its open-label extension for the treatment of ulcerative colitis patients. This article reviews the mechanism of action of etrasimod and summarizes the available clinical efficacy and safety data regarding etrasimod, which is a promising drug in the treatment of patients with moderate to severe ulcerative colitis.Lire moins >
Lire la suite >Sphingosine-1-phosphate (S1P) and its receptor (S1PR) are involved in the pathogenesis of multiple immune-mediated inflammatory disorders, including inflammatory bowel disease. The use of S1PR modulators represents a new therapeutic option for ulcerative colitis patients. Etrasimod is an oral selective S1PR1, S1PR4 and S1PR5 modulator that inhibits the trafficking of lymphocytes from the lymph nodes into the blood. Recently, etrasimod has demonstrated efficacy in the phase II OASIS study and its open-label extension for the treatment of ulcerative colitis patients. This article reviews the mechanism of action of etrasimod and summarizes the available clinical efficacy and safety data regarding etrasimod, which is a promising drug in the treatment of patients with moderate to severe ulcerative colitis.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Date de dépôt :
2024-02-01T22:06:48Z
2024-03-07T13:57:28Z
2024-03-07T13:57:28Z